Bristol-Myers Squibb Company (BMY) Cash Flow Statement

The wide quarterly swings in OCF/NI, from 0.41 to 2.87, suggest that net income is heavily influenced by non-cash items such as amortization and one-time charges, while cash generation remains more stable. The 2024Q1 net loss of $11.9B, driven by acquisition-related charges, contrasts with positive operating cash flow of $2.8B, highlighting that reported earnings understate the underlying cash-generating ability. Investors should focus on cash flow rather than GAAP earnings to assess the company's true financial health.

The FCF trajectory shows a sharp recovery from the 2026Q1 dip, driven by improved working capital management and stable capex. However, the 2026Q1 FCF margin of 6.6% was unusually low due to a $3.0B working capital outflow, which appears to be a timing issue rather than a structural deterioration. The average FCF margin over the last four quarters is approximately 18%, which is competitive with peers like MRK and PFE, indicating that BMY's cash generation remains resilient.

BMY's capex intensity is low relative to its revenue, averaging about 2.7% over the period, which is typical for a pharmaceutical company with outsourced manufacturing. This suggests that most of the company's capital is directed toward R&D and acquisitions rather than physical assets. The stability of capex indicates that the company is not in a major expansion phase, and the modest capex supports strong FCF conversion.

The large swings in working capital are likely due to the timing of collections from wholesalers and payments to suppliers, which can distort quarterly cash flow. The 2026Q1 outflow of $3.0B appears to be a temporary phenomenon, as it reversed in 2026Q2 with a smaller outflow. This volatility suggests that BMY's cash flow is subject to seasonal and operational factors, and investors should annualize cash flow to smooth out these fluctuations.

BMY's dividend payments have been consistent at around $1.3B per quarter, which represents a significant portion of FCF. With no buybacks in most quarters and occasional acquisition outflows, the company is prioritizing shareholder returns through dividends. However, this leaves less cash for debt reduction, which is important given the high debt levels from the Celgene acquisition. The sustainability of the dividend will depend on the company's ability to maintain FCF as patent expiries approach.

The large gap between cumulative net income and operating cash flow is primarily due to substantial amortization and impairment charges related to acquisitions, which reduce GAAP earnings but do not affect cash. This suggests that BMY's underlying cash-generating ability is stronger than its reported profitability. However, the gap also reflects the heavy use of acquisitions, which may not always create value. Investors should adjust for these non-cash charges to assess the company's true economic earnings.